1,2-Diazaspiro[3.5]nonane-7-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,2-Diazaspiro[3.5]nonane-7-carboxylic acid
• 英文别名: 1,2-diazaspiro[3.5]nonane-7-carboxylic acid
• 化学式: C₈H₁₄N₂O₂
• 分子量: 170.21
• InChiKey: BQVAACLXDXFMOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS<br/>[FR] ANALOGUES DE NUCLÉOSIDES SUBSTITUÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017153186A1

  公开（公告）日：2017-09-14

  The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式(I)的新型取代核苷类似物，其中变量具有如权利要求中所定义的含义。根据本发明的化合物作为PRMT5抑制剂是有用的。本发明进一步涉及包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的应用。
• [EN] NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE<br/>[FR] NOUVEAUX COMPOSÉS DIAZASPIROCYCLOALCANE ET AZASPIROCYCLOALCANE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013186159A1

  公开（公告）日：2013-12-19

  The invention provides novel compounds having the general formula (I), wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般公式（I）的新化合物，其中R1、R2、Y和W如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• [EN] ENANTIOMERICALLY PURE ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION<br/>[FR] DÉRIVÉS ÉNANTIOMÉRIQUEMENT PURS D'ADAMATANE POUR LE TRAITEMENT D'INFECTIONS À FILOVIRUS
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2019018185A1

  公开（公告）日：2019-01-24

  The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. Structure I X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyi, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburgvirus.

  本发明的化合物如一般结构I所示，如下所示，对于治疗丝状病毒感染具有有效性。 结构I中X的选择来自于O和H的群组; R1的选择来自于（C6到C10）芳基和（C2到C9）杂环芳基，而R2的选择来自于（C1到C10）烷基，（C1到C10）烯基，（C1到C10）炔基，（C3到C10）环烷基和（C5到C10）环烯基，而NR3aR3b在规范中被定义。 这些化合物对于治疗丝状病毒感染包括埃博拉病毒和马尔堡病毒具有有效性。
• MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：ARENA PHARMACEUTICALS, INC.

  公开号：US20140309192A1

  公开（公告）日：2014-10-16

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

  本发明涉及公式（I）的化合物及其药学上可接受的盐、溶剂合物和水合物，这些化合物对于治疗和缓解由缺血引起的心脏、脑、肾脏、免疫和生殖系统的疾病和障碍以及缺血后再灌注及其相关的任何下游并发症具有用处。本发明还涉及治疗和缓解由血管收缩或高血压引起的血管病变及由升高的血压和/或组织灌注减少引起的任何下游并发症的方法。
• NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2861566A1

  公开（公告）日：2015-04-22